A prospective population-based management program including primary surgery and postoperative risk assessment by means of DNA ploidy and histopathology. Adjuvant radiotherapy is not necessary for the majority of patients with FIGO stage I-II endometrial cancer
(2004) In International Journal of Gynecological Cancer 14(3). p.437-450- Abstract
- A management program for FIGO stage I-II nonserous, nonclear-cell adenocarcinomas was evaluated. Histopathology and DNA ploidy were used to estimate postoperatively the risk of progression or death of disease and to tailor treatment. The patient material was a population-based consecutive cohort of all women with endometrial cancer in the Southern Swedish Health Care Region diagnosed between June 1993 and June 1996 (n = 553). Of these, 335 were eligible for the management program. Patients estimated to be at low risk were treated by surgery only, while high-risk patients also received vaginal brachytherapy. A large low-risk group consisting of 84% (n = 283) of the patients with an estimated disease-specific 5-year survival of 96% (95% CI =... (More)
- A management program for FIGO stage I-II nonserous, nonclear-cell adenocarcinomas was evaluated. Histopathology and DNA ploidy were used to estimate postoperatively the risk of progression or death of disease and to tailor treatment. The patient material was a population-based consecutive cohort of all women with endometrial cancer in the Southern Swedish Health Care Region diagnosed between June 1993 and June 1996 (n = 553). Of these, 335 were eligible for the management program. Patients estimated to be at low risk were treated by surgery only, while high-risk patients also received vaginal brachytherapy. A large low-risk group consisting of 84% (n = 283) of the patients with an estimated disease-specific 5-year survival of 96% (95% CI = 93-98%) was identified. The high-risk group (n = 52, 16%) showed a worse outcome with an 80% 5-year disease-specific survival (95% CI = 65-89%). The difference in survival between the groups was highly significant (P < 0.0001). Half of the progressions were distant in the high-risk group. Although there is a clear indication for adjuvant therapy for this group, locoregional radiotherapy could be expected to fail in cases with distant progression. Thus, effective systemic treatments need to be developed. Low-risk patients, constituting the majority (84%) of the patients, can be safely treated by surgery only. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/276230
- author
- Hogberg, T ; Fredstorp-Lidebring, M ; Alm, Per LU ; Baldetorp, Bo LU ; Larsson, G ; Ottosen, C ; Svanberg, L and Lindahl, Bengt LU
- organization
- publishing date
- 2004
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- prospective studies, endometrial neoplasms/therapy, ploidies, risk, factors
- in
- International Journal of Gynecological Cancer
- volume
- 14
- issue
- 3
- pages
- 437 - 450
- publisher
- BMJ Publishing Group
- external identifiers
-
- wos:000221794500004
- scopus:2942622416
- ISSN
- 1048-891X
- DOI
- 10.1111/j.1048-891x.2004.014303.x
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Department of Obstetrics and Gynaecology (Lund) (013018000), Oncology, MV (013035000), Pathology, (Lund) (013030000)
- id
- 77ba57b2-dd29-4332-bfd3-8695f46242c7 (old id 276230)
- alternative location
- http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=15228416&dopt=AbstractPlus
- date added to LUP
- 2016-04-01 12:21:24
- date last changed
- 2022-07-15 08:49:14
@article{77ba57b2-dd29-4332-bfd3-8695f46242c7, abstract = {{A management program for FIGO stage I-II nonserous, nonclear-cell adenocarcinomas was evaluated. Histopathology and DNA ploidy were used to estimate postoperatively the risk of progression or death of disease and to tailor treatment. The patient material was a population-based consecutive cohort of all women with endometrial cancer in the Southern Swedish Health Care Region diagnosed between June 1993 and June 1996 (n = 553). Of these, 335 were eligible for the management program. Patients estimated to be at low risk were treated by surgery only, while high-risk patients also received vaginal brachytherapy. A large low-risk group consisting of 84% (n = 283) of the patients with an estimated disease-specific 5-year survival of 96% (95% CI = 93-98%) was identified. The high-risk group (n = 52, 16%) showed a worse outcome with an 80% 5-year disease-specific survival (95% CI = 65-89%). The difference in survival between the groups was highly significant (P < 0.0001). Half of the progressions were distant in the high-risk group. Although there is a clear indication for adjuvant therapy for this group, locoregional radiotherapy could be expected to fail in cases with distant progression. Thus, effective systemic treatments need to be developed. Low-risk patients, constituting the majority (84%) of the patients, can be safely treated by surgery only.}}, author = {{Hogberg, T and Fredstorp-Lidebring, M and Alm, Per and Baldetorp, Bo and Larsson, G and Ottosen, C and Svanberg, L and Lindahl, Bengt}}, issn = {{1048-891X}}, keywords = {{prospective studies; endometrial neoplasms/therapy; ploidies; risk; factors}}, language = {{eng}}, number = {{3}}, pages = {{437--450}}, publisher = {{BMJ Publishing Group}}, series = {{International Journal of Gynecological Cancer}}, title = {{A prospective population-based management program including primary surgery and postoperative risk assessment by means of DNA ploidy and histopathology. Adjuvant radiotherapy is not necessary for the majority of patients with FIGO stage I-II endometrial cancer}}, url = {{http://dx.doi.org/10.1111/j.1048-891x.2004.014303.x}}, doi = {{10.1111/j.1048-891x.2004.014303.x}}, volume = {{14}}, year = {{2004}}, }